TY - JOUR
AB - NEJM.org The most This week in the journal recently published online first recent articles ORIGINAL ARTICLES Economic Effects of Medicaid Expansion are available Ocrelizumab in Primary Progressive Multiple Sclerosis in Michigan online now. Patients with primary progressive MS who received the Intimate Choices, Public Threats — anti-CD20+ humanized antibody ocrelizumab were less Reproductive and LGBTQ Rights likely to have clinical deterioration that was sustained for under a Trump Administration 12 weeks than those who received placebo. The drug was associated with decreased lesion activity on MRI. Repealing the ACA without a Replacement Editorial, CME, Commenting, PPT slides — The Risks to American Health Care videos, images, and multimedia Ocrelizumab vs. Interferon Beta-1a in Relapsing MS Images in Clinical Medicine NEJM archive In two trials involving patients with relapsing multiple Swirl Sign after Gastric Bypass sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab A 56-year-old man The complete archive of all Journal was associated with lower annualized relapse rates, lower who had undergone content includes risk of disability progression, and better MRI features than gastric bypass 7 years A Controlled Therapeutic Study interferon beta-1a. earlier presented with of the Irritable-Bowel Syndrome — Editorial, PPT slides midabdominal pain, nausea, and Effect of Diphenylhydantoin 
TI - This Week in the Journal
JF - The New England Journal of Medicine
DO - 10.1056/NEJMtwj170119
DA - 2017-01-19
UR - https://www.deepdyve.com/lp/the-new-england-journal-of-medicine/this-week-in-the-journal-8OcUMCDzXp
SP - 208
EP - 208
VL - 376
IS - 3
DP - DeepDyve
ER -